Welcome to The World’s Definitive Degrader & Proximity-Based Drugs Event
Accelerating the Discovery, Development & Approval of First-In-Class Selective, Safe & Efficacious Degraders & Proximity-Based Drugs to Target the Undruggable
As the TPD field eagerly awaits the approval of Arvinas’s Vepdegestrant, and with C4 Therapeutics and Kymera progressing through Phase 1 and 2 clinical trials, 2025 is poised to be the year of clinical validation for TPD. This has been echoed in the flurry of partnerships worth over $200M in 2025 alone, with the majority of big pharma now invested in molecular glues, PROTACs, or novel induced proximity drugs.
Returning as the industry’s definitive forum from early discovery to clinical development, the 8th Annual TPD & Induced Proximity Summit is the world’s largest and longest-standing forum for proximity-based modalities, enabling you to fully immerse yourself in the breadth and depth of cutting-edge induced proximity therapeutic development.
The PCI Pharma Services team will be available throughout the event to discuss your Targeted Protein Degrader needs.
For more information or to register for this event, please see the event website
Details:
Event: 8th Annual TPD and Induced Proximity Summit
Date: 27-30 Oct 2025
Where: The Westin Boston Seaport District
Country: USA
